Medicon Village
Scheelevägen 2
Lund 223 81
Sweden
46 1 03 00 10 23
https://synactpharma.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 5
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Mr. Jeppe Ovli Ovlesen EE, MBA | CEO & Director | 3,66M | S.O. | 1962 |
Mr. Bjorn Westberg | Chief Financial Officer | S.O. | S.O. | 1962 |
Dr. Thomas Boesen Ph.D. | Chief Operating Officer | S.O. | S.O. | S.O. |
Mr. James Knight M.B.A. | Chief Business Officer | S.O. | S.O. | S.O. |
Ms. Kristen Harting M.D. | Chief Medical Officer | S.O. | S.O. | S.O. |
SynAct Pharma AB, a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis, idiopathic membranous nephropathy, and virus-induced respiratory insufficiency. It is developing TXP-11, an advanced peptide agonist that is in preclinical trials for the prevention of organ failure in surgery; and various drug programs to treat auto-immune and inflammatory diseases. SynAct Pharma AB was founded in 2012 and is headquartered in Lund, Sweden.
L’ISS Governance QualityScore de SynAct Pharma AB en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..